Wednesday 26 November 2014, Amsterdam
The table below provides the key metrics for coronary stents in the 10 major markets (10MM) (US, France, Germany, Italy, Spain, UK, Japan, Brazil, China, and India) during the forecast period from 2013–2020.
Coronary Stent Sales by Region Coronary stents can be used for a wide range of indications in coronary artery disease (CAD), including de novo lesions, small-vessel disease (SVD), bifurcation lesions, and tortuous and narrow lesions. Coronary stents can improve the clinical outcomes for all of these indications as well as quality of life for patients suffering from this debilitating disease.
The figure below shows the sales of coronary stents for treating CAD in each of the 10 countries covered in this report during the forecast period. In 2013, sales of DES and BMS in the 10MM were $4.89 billion. GlobalData estimates the 2014 sales of DES and BMS in the 10MM to be $4.99 billion. By 2020, sales of coronary stents, including bare metal and drug-eluting stents, will grow to $5.62 billion, at a Compound Annual Growth Rate (CAGR) of 2.0%. To date, BAS have not received regulatory approval and been launched in the US, Japanese, and Chinese markets, but are expected to enter these markets in the near future.
Of the 10MM covered in the report, the US currently has and will continue to have the largest share in the coronary stents market. Together, the US, the 5EU countries, and Japan will account for 64% of the coronary stents market for BMS and DES in 2020. Collectively, the 5EU countries are forecast to have only 10% market share in the future. Among the emerging markets, China has captured significant market share, which is expected to increase in the future. The emerging markets, including Brazil, China, and India, are expected to demonstrate the greatest growth in the market over the forecast period and will serve as an outlet of expansion for stent manufacturers to increase their global presence.
The key drivers for the coronary stents market during the forecast period are:
- The rising prevalence of CAD in the major markets covered in this report
- The need for effective therapies that reduce the risk of complications, such as restenosis (re-narrowing of the coronary artery), chronic inflammation, and thrombosis, and the need for target lesion revascularization (TLR) associated with bare metal and drug-eluting stenting
- The cost savings for healthcare payers resulting from the reduced need for repeat revascularization procedures and prolonged dual antiplatelet therapy
- Reducing the need for stent-in-stent procedures and improving the technical feasibility of future interventions
- Innovations in stent technology with regard to the platform, material, and coating
- The increase in patients’ disposable income and government insurance coverage in the emerging markets, such as China and India
- The approval and launch of BAS, such as the Absorb BVS, in the US, Japan, and China
Market Dynamics
Stenting for coronary applications has been widely adopted in clinical practice and is associated with improved outcomes. BMS and DES are effectively commodities, where the physician has a handful of stents from which to choose. Within the coronary stents market, DES currently dominate the market and will continue to do so throughout the forecast period, as they are considered the gold standard of treatment. The DES market is a vast and double-digit market, accounting for nearly 90% of the total coronary stent market, as shown in the figure below. In fact, DES sales for coronary applications are nearly eight times those of BMS market sales. Given this large market potential and the rising prevalence of CAD worldwide, device manufacturers have focused primarily on the research and development (R&D) and commercialization of innovative DES systems. The larger market sales of DES can be attributed to physicians’ extensive clinical experience and expertise in using these stents, improved outcomes, and the reduced need for repeat intervention. BMS are used in cases where the patient is not a good candidate to receive a DES, such as those planning to undergo other major surgeries in the near future. Covered stents (CS) are used less often in practice and only in select cases, such as patients with artery perforations. BAS have only recently entered the market and are not widely adopted in clinical practice, due to the lack of clinical evidence and the high cost of these devices.
ASDReports.com contact: S. Koomen
ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216
back to News
